CAM
BIIB icon

Concorde Asset Management’s Biogen BIIB Stock Holding History

Concorde Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-917
Closed -$281K – 117
2015
Q4 		$281K Buy
+917
New +$264K 0.31% 82

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Concorde Asset Management's BIIB Position: Q1 2016 in Review

Concorde Asset Management sold out of Biogen (BIIB) in Q1 2016, closing a stake of 917 shares — an estimated $281K sold.

Concorde Asset Management first reported a position in BIIB in Q4 2015 and held it in 1 quarter. The position peaked at $281K in Q4 2015. 947 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Concorde Asset Management reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Concorde Asset Management sold 917 Biogen shares in Q1 2016, an estimated $281K.
  • Concorde Asset Management first reported a position in Biogen in Q4 2015 and held it in 1 quarter.
  • Concorde Asset Management's Biogen position peaked at $281K in Q4 2015.
  • 947 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Concorde Asset Management's 13F filing for Q1 2016, filed 26 Apr 2016.